BioNTech Investor Day Presentation Deck
mRNA vaccines for enabling potent multi-targeting of cancers
IV injection of RNA-LPX
2
decatopes
Delivery
of RNA-LPX to
dendritic cells in
lymphoid
compartments
Spleen
Dendritic cell
CD8 T cell
CD4 T cell
RNA-LPX
Dendritic cell
Innate immune stimulation
Endosome
Polypeptide
mRNA
TLR 7/8
MHCI
Proteasome
NF-KB
Endoplasmic
TAP. reticulum
Endo-lysosomes
Antigen presentation
MHCII
TCR
Co-stimulatory
molecules
Pro-inflammatory
cytokines
CD80 CD28
MHCI TCR
Kranz LM, et al. Nature 2016; 534:396-401; Lopez J, et al. AACR Annual Meeting 2020; Oral presentation CT301.
* Collaboration with Genentech.
CD40
CD40L
CD8 T cell
stimulation
Cytokine
help
CD4 T cell
stimulation
Backbone optimized uridine mRNA (URNA)
Cap UTR Antigen
Neo-
antigens
Individualized
therapy
iNeST*
individualized
Neoantigen-Specific
immunoTherapy
UTR
NUM
mRNA cancer vaccines
A30-L-A70
Multiple shared
antigens
Off-the-shelf
therapy
Fix Vac
Fixed Antigen
Vaccine
6668
ĉ
BIONTECH 96View entire presentation